CAP TODAY Webinars

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine, Department of Pathology, SOM at Johns Hopkins University, discusses how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC, discusses how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenters Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark, discuss how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Join David Gonzalez, PhD, FRCPath, one of the leading experts in the EuroClonality-NGS working group of the Euroclonality consortium, dedicated to advancing standardized diagnostics in hematology-oncology, to learn:

• How EuroClonality-NDC and Myeloid-NDC NGS Workflows are utilized in advancing the future of diagnostics, prognostics, and targeted therapies.

• How these revolutionary assays provide comprehensive genomic data that reveals mutations, structural variations, and clonal evolution patterns with remarkable resolution, enabling clinical researchers to delve deeper into the genomic landscape of hematological malignancies.